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Positron emission tomography imaging of dementia
• Alzheimer’s disease is prevalent and costly, but can be treated, especially in the early stages;
• The current approach to dementia diagnosis involves multiple, costly assessments;
• Positron emission tomography (PET) provides early positive differential diagnosis for Alzheimer’s disease
and other dementias;
• Brain PET images show characteristic patterns that differentiate dementias (Figure 1).
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Figure 1. Characteristic PET patterns 
for cognitively intact normal persons 
(left image) and other dementias,
including parietal deficits in
Alzheimer’s disease, frontal deficits in
Pick’s disease, irregular cortical and
subcortical deficits for multi-infarct
dementia, and caudate deficits in
Huntington’s disease. Arrows indicate
light gray areas of decreased cerebral
glucose metabolism.
• By contrast, structural imaging
(eg, magnetic resonance 
imaging [MRI]) often shows
nonspecific atrophy or focal
lesions (Figure 2).
Figure 2. MRI scan (left) and PET scan
(right) of the same patient with proba-
ble Alzheimer’s disease. The MRI scans
shows generalized atrophy and white
matter hyperintensities, which can be
nonspecific findings. By contrast, the
PET scan shows the parietal and tem-
poral deficits (lighter areas) that are
characteristic of Alzheimer’s disease.
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Figure 3. PET scans showing glucose 
metabolism at the level of the
parietal lobe (upper images) and
temporal lobe (lower images). 
The parietal, temporal, and frontal
hypometabolism progresses from
early- to late-stage Alzheimer’s 
disease, sparing the occipital cortex,
deep structures, and the
sensorimotor strip.
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• The characteristic parietal and temporal deficits of Alzheimer’s disease may appear several years
prior to clinical confirmation of probable diagnosis. These deficits progress along with severity of
dementia. Eventually, the frontal cortex becomes hypometabolic as well (Figure 3).
• Nondemented older people with the apolipoprotein E4 (APOE-4) genetic risk for Alzheimer’s disease
may have lower parietal metabolism on PET compared with their counterparts without APOE-4 (Figure 4).
• Longitudinal PET measures of brain metabolism in combination with genetic risk information on
Alzheimer’s disease (eg, APOE genotype) may be useful for determining effects of drugs used to
treat age-related cognitive decline.
Figure 4. Subject with normal
memory performance and the APOE-
4 genetic risk for Alzheimer’s disease
(middle scans) showing decreased
parietal metabolism (arrowheads),
compared with a subject without
APOE-4 (left scan). The parietal
hypometabolism in a patient with
dementia (right scan) is even more
pronounced (arrowheads).
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